The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 11 - 20 of 46
Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents
This article from Clinical Infectious Diseases examines the potential of injectable PrEP for HIV prevention in infants, children, and adolescents.
Research, Service Delivery
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries
This article from Clinical Infectious Diseases examines potential barriers to scale-up of injectable PrEP in low and middle income countries.
Research, Service Delivery
Long-acting Injectable Cabotegravir (CAB for PrEP) for HIV Prevention: Community perspectives
During this 90-minute webinar, speakers will discuss community acceptability of and preferences for different PrEP options, including CAB for PrEP, barriers to implementation of CAB for PrEP, and engagement with communities as CAB for PrEP projects are being planned. This webinar is presented by the Global PrEP Network, a WHO-led forum designed to facilitate global…
Community/Advocacy, Service Delivery
A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia
This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.
Demand Creation/Marketing, Service Delivery
Relative Cost-effectiveness of Long-acting Injectable Cabotegravir versus Oral Pre-exposure Prophylaxis in South Africa based on the HPTN 083 and HPTN 084 Trials: A modelled economic evaluation and threshold analysis
This article from The Lancet HIV estimates the incremental cost-effectiveness of long-acting injectable cabotegravir (CAB for PrEP) compared with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC oral PrEP) in South Africa, using methods standard to government planning, and determines the threshold price at which CAB for PrEP is as cost-effective as TDF/FTC oral PrEP.
Financing & Costing, Research
Long-acting injectable cabotegravir for HIV prevention: WHO guidelines, implementation considerations, and project examples
Recording During this 90-minute webinar, speakers will provide an overview of the new WHO guidelines on CAB for PrEP, discuss implementation issues specifically relating to HIV testing and drug resistance, and highlight examples of planned implementation projects in sub-Saharan Africa and Asia. This webinar is presented by the Global PrEP Network, a WHO-led forum designed…
Research, Normative Guidance/Policies, Testing
Acceptability of Injectable Pre-exposure Prophylaxis among People who Inject Drugs in Three Urban U.S. Settings
This article from BMC Infectious Diseases examines acceptability of injectable PrEP amongst people who inject drugs in the US.
Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?
This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.
Monitoring & Evaluation, Research, Testing
Coordinating Implementation Science for CAB for PrEP: Focus on Delivery Models
This second meeting of the BioPIC implementation science series focused on how cabotegravir (CAB) for PrEP can be integrated into existing community, pharmacy and facility-based delivery for HIV prevention.
More than Just Oral PrEP: Exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor
This exploratory and cross-sectional study investigated interest in four biomedical prevention tools—rectal douche, dissolvable implant, removable implant and injection—among a racially diverse sample of men who have sex with men from the Northeast Corridor region between Philadelphia and Trenton.